Phage Predation: Killing the killers
Bacteriophages are viruses that prey on bacteria. Also known as phages, they can multiply very quickly—hundreds of new viruses can be produced in a single infected bacterium in less than 30 minutes. However, relatively little is known about the impact of phage predation on human-associated bacteria in general, and even less on bacterial pathogens. Now, in eLife, Andrew Camilli of Tufts University School of Medicine and co-workers in Canada, Haiti and the United States, provide molecular evidence that phages prey on a bacterial pathogen during the course of an infection in humans (Seed et al., 2014).
Vibrio cholerae is the bacterium responsible for cholera. After being ingested, typically by drinking contaminated water, it multiplies in the digestive tract where it releases a toxin. This toxin causes profuse and watery diarrhoea, dehydration and death in 50% of cases if rehydration therapy is not administered.
In the delta region of the river Ganges in Bangladesh and India, cholera epidemics occur every year, and follow regular seasonal cycles. It has been proposed that this seasonal variation might be partly related to phages preying on the V. cholera bacteria—as the so-called vibriophages are most common in environmental waters at the end of the cholera season (Faruque et al., 2005a, 2005b).
Camilli and co-workers—including Kimberley Seed as the first author—report molecular data that indicate that vibriophages may preferentially prey on bacteria in the digestive tract of patients with cholera, rather than in environmental waters (Seed et al., 2014). Seed et al. looked at stool samples from two cholera patients (one from Haiti, one from Bangladesh) who had high viral loads of a type of vibriophage called ICP2. In each sample, they discovered that some of the bacteria were resistant to the phage, while the rest were sensitive to it. Then, Seed et al. sequenced the whole genomes of bacterial clones and discovered that the only differences between the phage-resistant and phage-sensitive isolates in each patient were clustered into a single gene. However, a different bacterial gene was mutated in each patient. Several different mutants of each gene were found. This strongly suggests that these mutations occurred, and were then selected for, in bacteria in the patient during the infection.
In the Haitian patient, almost all (> 99%) of the bacteria isolated were resistant to the phage; and, of the phage-resistant bacteria tested, all had one of six different mutations in a single gene called ompU. The OmpU protein forms a pore in the bacteria’s outer membrane to enable nutrients to be imported into the cell. The bacteria need this protein for their survival both in human hosts and in environmental waters. Since the OmpU mutants are resistant to phage attack, Seed et al.’s findings indicate that the OmpU protein is also used by the vibriophage ICP2 to infect the bacterial cells (i.e. it is also the ‘receptor’ for the ICP2 phage).
Seed et al. show that the selection of OmpU mutants by ICP2 vibriophages is not restricted to this isolated case. Out of a collection of 54 clinical isolates of V. cholerae collected in Bangladesh between 2001 and 2011, 15% have similar phage-resistant mutations in the ompU gene. Seed et al. also found that the changes in the OmpU protein were all in parts of the protein that are exposed on the outside of the bacterial cell; and importantly, that they had very little effect on the fitness of V. cholerae in a range of tests. This is reminiscent of the relationship between the bacterium E. coli and the phage lambda, where mutations in a surface protein can make the bacteria resistant to phage attack. These mutations also occur in a surface-exposed part of the protein and do not affect the other functions of this protein (Gehring et al., 1987; Hofnung, 1995). However, the E. coli/phage lambda studies were performed in the laboratory, whereas this V. cholerae study appears to be the first report that suggests a predator-prey relationship between phage and bacteria in the human intestine.
In the stool sample from the Bangladeshi patient, 22% of bacterial isolates were resistant to the ICP2 phage; and Seed et al. identified four different genetic changes that made the bacteria able to resist this phage attack. All of these mutations were in a gene called toxR, which encodes a protein that regulates the expression of numerous genes, including ompU. Since these ToxR mutants do not produce the phage’s receptor—the OmpU protein—this confers resistance to phage attack. However, the ToxR protein also regulates genes that control the virulence of the bacteria, and the ToxR mutants were unable to start new infections in an animal model of cholera. Therefore, in contrast with the OmpU mutants, it is more difficult to unambiguously assign the selection of ToxR mutants as resulting solely from defending against phage attack. Instead the selection of these non-infectious mutants could also be explained by such mutations making it ‘cheaper’ for these bacteria to grow in the digestive tract at the expense of the virulent clones.
Although it is perhaps counterintuitive, mutations that reduce virulence can have a selective advantage during an infection (Diard et al., 2013). Expressing so-called virulence proteins or factors is costly for an individual bacterium, and mutants that stop making these factors can, therefore, benefit at the expense of other bacteria that continue to do so. This advantage, however, is only short-lived as these less virulent mutants are unable to start new infections themselves. Regardless of the precise mechanism, the selection for the non-infectious ToxR mutants observed by Seed et al. suggests that phage predation may have contributed to the collapse of the infection and the selection of less virulent strains.
Finally, the results of Seed et al., together with the previous work by other groups that it builds on, highlight the important role that phages can play in shaping V. cholerae populations. These findings firmly place these viruses as an important ‘third’ party that must also be considered when trying to understand host–pathogen interactions.
References
-
Self-limiting nature of seasonal cholera epidemics: role of host-mediated amplification of phageProceedings of the National Academy of Sciences of USA 102:6119–6124.https://doi.org/10.1073/pnas.0502069102
-
Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phagesProceedings of the National Academy of Sciences of USA 102:1702–1707.https://doi.org/10.1073/pnas.0408992102
-
Bacteriophage lambda receptor site on the Escherichia coli K-12 LamB proteinJournal of Bacteriology 169:2103–2106.
Article and author information
Author details
Publication history
Copyright
© 2014, De Paepe and Petit
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,115
- views
-
- 83
- downloads
-
- 3
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Immunology and Inflammation
- Microbiology and Infectious Disease
Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.
-
- Microbiology and Infectious Disease
The persistence of latent viral reservoirs remains the major obstacle to eradicating human immunodeficiency virus (HIV). We herein found that ICP34.5 can act as an antagonistic factor for the reactivation of HIV latency by herpes simplex virus type I (HSV-1), and thus recombinant HSV-1 with ICP34.5 deletion could more effectively reactivate HIV latency than its wild-type counterpart. Mechanistically, HSV-ΔICP34.5 promoted the phosphorylation of HSF1 by decreasing the recruitment of protein phosphatase 1 (PP1α), thus effectively binding to the HIV LTR to reactivate the latent reservoirs. In addition, HSV-ΔICP34.5 enhanced the phosphorylation of IKKα/β through the degradation of IκBα, leading to p65 accumulation in the nucleus to elicit NF-κB pathway-dependent reactivation of HIV latency. Then, we constructed the recombinant HSV-ΔICP34.5 expressing simian immunodeficiency virus (SIV) env, gag, or the fusion antigen sPD1-SIVgag as a therapeutic vaccine, aiming to achieve a functional cure by simultaneously reactivating viral latency and eliciting antigen-specific immune responses. Results showed that these constructs effectively elicited SIV-specific immune responses, reactivated SIV latency, and delayed viral rebound after the interruption of antiretroviral therapy (ART) in chronically SIV-infected rhesus macaques. Collectively, these findings provide insights into the rational design of HSV-vectored therapeutic strategies for pursuing an HIV functional cure.